Compare Adaptive Biotechnologies Corp (ADPT) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Williams-Sonoma, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while Williams-Sonoma, Inc. trades at $216.82 (market cap $26.36B). The key difference: Williams-Sonoma, Inc. is far larger — about 7.9× Adaptive Biotechnologies Corp's market cap, and Williams-Sonoma, Inc. pays a 1.36% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | WSM | |
|---|---|---|
Market Cap | $3.33B | $26.36B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $240.06 |
52-Week Low | $10.24 | $163.62 |
Enterprise Value | $3.19B | $27.20B |
Dividend Yield | — | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Williams-Sonoma (WSM) trades at $222.49, down 2.22% today, with a bullish technical signal and strong profitability metrics including 54.01% ROE and 13.81% net margin. The stock has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $2.03. Recent news highlights brand collaborations and dividend declarations, while cash flow trends show operational strength despite net outflows in 2025.
WSM presents a mixed outlook with robust fundamentals and analyst consensus leaning hold (60.72%), but risks include competitive pressures and macroeconomic sensitivity. The current price sits above the $215.50 consensus target, suggesting limited near-term upside despite strong operational performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
